Atossa Genetics Inc
$ 0.66
-3.99%
26 Dec - close price
- Market Cap 85,111,000 USD
- Current Price $ 0.66
- High / Low $ 0.69 / 0.65
- Stock P/E N/A
- Book Value 0.38
- EPS -0.23
- Next Earning Report 2026-04-01
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.49 %
- 52 Week High 1.29
- 52 Week Low 0.55
About
Atossa Genetics Inc. is a Seattle-based clinical-stage biopharmaceutical company dedicated to pioneering innovative therapies for breast cancer and infectious diseases. With a strong focus on addressing significant unmet medical needs, the company boasts a diverse pipeline of advanced product candidates that leverage cutting-edge drug delivery systems and formulations. Atossa is committed to improving patient outcomes through targeted therapies, positioning itself as a leader in pharmaceutical innovation within the rapidly evolving healthcare sector.
Analyst Target Price
$5.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-17 | 2025-08-12 | 2025-05-13 | 2025-03-31 | 2024-11-11 | 2024-08-12 | 2024-05-13 | 2024-03-28 | 2023-11-13 | 2023-08-14 | 2023-05-15 | 2023-03-22 |
| Reported EPS | -0.07 | -0.07 | -0.05 | -0.05 | -0.0575 | -0.05 | -0.05 | -0.09 | -0.05 | -0.08 | -0.05 | -0.06 |
| Estimated EPS | -0.0633 | -0.06 | -0.07 | -0.0633 | -0.06 | -0.06 | -0.07 | -0.06 | -0.07 | -0.06 | -0.06 | -0.06 |
| Surprise | -0.0067 | -0.01 | 0.02 | 0.0133 | 0.0025 | 0.01 | 0.02 | -0.03 | 0.02 | -0.02 | 0.01 | 0 |
| Surprise Percentage | -10.5845% | -16.6667% | 28.5714% | 21.0111% | 4.1667% | 16.6667% | 28.5714% | -50% | 28.5714% | -33.3333% | 16.6667% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-01 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.0675 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATOS
2025-12-18 06:09:09
Atossa Therapeutics, Inc. has been honored with the 2025 Clinical Trials Arena Research and Development Excellence Award in the Precision Endocrine Therapy category for its work on (Z)-endoxifen. This innovative therapy is a potent selective estrogen receptor modulator/degrader being evaluated for use in various breast cancer settings and Duchenne Muscular Dystrophy. The award recognizes Atossa's commitment to advancing precision endocrine therapy through biomarker-driven studies and proactive regulatory engagement.
2025-12-17 20:09:09
Atossa Therapeutics has received the Research and Development award for Precision Endocrine Therapy at the 2025 Clinical Trials Arena Excellence Awards for its work on (Z)-endoxifen. This innovative therapy reframes a long-standing prodrug concept into a precision, exposure-controlled endocrine agent, bypassing limitations of traditional tamoxifen. The company's approach combines molecular-marker driven clinical trials, adaptive Phase 2 designs, and proactive regulatory engagement across various breast cancer settings and Duchenne Muscular Dystrophy.
2025-12-17 13:09:13
Atossa Therapeutics, Inc. has been awarded the 2025 Clinical Trials Arena Research and Development Excellence Award in the Precision Endocrine Therapy category. This recognition highlights their innovative work on (Z)-endoxifen, a precision-engineered endocrine therapy with potential applications across multiple breast cancer indications and Duchenne Muscular Dystrophy. The award acknowledges the company's commitment to scientific rigor, innovation, and leadership in clinical research.
2025-12-17 08:15:00
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has been awarded the 2025 Clinical Trials Arena Research and Development Excellence Award in the Precision Endocrine Therapy category. This recognition highlights their innovative work in advancing (Z)-endoxifen, a precision-engineered endocrine therapy for various breast cancer indications and Duchenne Muscular Dystrophy. The company is commended for its commitment to scientific rigor, innovation, and leadership in clinical research.
2025-12-17 08:15:00
Atossa Therapeutics, Inc. has been awarded the 2025 Clinical Trials Arena Research and Development Excellence Award in the Precision Endocrine Therapy category for its innovative work on (Z)-endoxifen. This recognition highlights the company's commitment to developing precision-engineered endocrine therapies for unmet medical needs across various breast cancer settings and Duchenne Muscular Dystrophy. The award underscores Atossa's integrated approach to clinical studies, regulatory engagement, and its potential to significantly impact patient populations.
2025-12-15 13:09:27
Atossa Therapeutics presented four clinical trial updates on (Z)-endoxifen at the 2025 San Antonio Breast Cancer Symposium, highlighting its potential in breast cancer treatment and risk reduction. The presentations covered initial results from RECAST DCIS, low-dose (Z)-endoxifen in the I-SPY2 trial, (Z)-endoxifen's function against ESR1 mutants, and the EVANGELINE trial for premenopausal women. These updates reinforce the therapeutic value of (Z)-endoxifen and the company's commitment to advancing clinical programs for breast cancer care.
